Aurobindo’s Unit 1 clears USFDA audit with zero observations

Smart Money Financial Services :-

Aurobindo’s Unit 1 has cleared USFDA inspection with zero observations. Unit 1 is an API unit with manufacturing capabilities in CVS, CNS, anti-allergics and non-sterile Cephalosporins. The audit started on April 16 and ended on April 20, 2018.

Aurobindo Pharma Ltd is currently trading at Rs637.40 up by Rs18.9 or 3.06% from its previous closing of Rs618.50 on the BSE.


Comments

Popular posts from this blog

Top intraday trading ideas for afternoon trade for Monday 31 December 2018

WELCOME TO SMART MONEY FINANCIAL SERVICES

F&O: Put writing at all immediate strikes shows Nifty may hold up